A comparative analysis of the survival between GD2-positive and GD2-negative tumors among patient subgroups defined by breast cancer subtypes was limited by the small number of cases in the TNBC and HER2+ subsets and did not reveal any associations between GD2 positivity and DFS (Figure S4) or OS (Figure S5). This evidence concerns the gene ERBB2 and breast cancer.